only with
Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s Lab
Dr. Reddy’s Laboratories Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Large-cap - With a market cap of ₹1115.89 Cr.
| EX-Date | Purpose |
|---|---|
| 27 07 2021 | Quarterly Results |
| 29 10 2021 | Quarterly Results |
| 28 01 2022 | Quarterly Results |
| 19 05 2022 | Final Dividend & Audited Results |
| 28 07 2022 | Quarterly Results |
| 28 10 2022 | Quarterly Results |
| 25 01 2023 | Quarterly Results |
| 10 05 2023 | Audited Results & Final Dividend |
| 26 07 2023 | Quarterly Results |
| 07 05 2024 | Audited Results & Final Dividend |
| 05 11 2024 | Quarterly Results |
| 23 01 2025 | Quarterly Results |
| 09 05 2025 | Final Dividend |
| 23 07 2025 | Quarterly Results |
| 24 10 2025 | Quarterly Results |
| 21 01 2026 | Quarterly Results |
| 12 05 2026 | Audited Results & Quarterly Results |
News
Dr. Reddy’s Laboratories reports 86% plunge in Q4FY26 consolidated net profit
Consolidated total income of the company decreased by 11.37% at Rs 8,021.80 crore for Q4FY26
Dr. Reddy’s Lab gets Health Canada’s nod for Generic Semaglutide Injection
The company becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada
Dr. Reddy’s Laboratories to sell entire shareholding in Svaas Wellness
Consequent to the completion of the transaction, Svaas Wellness will cease to be a wholly owned subsidiary of the Company
Dr. Reddy’s Laboratories launches Semaglutide injection ‘Obeda’ for Type 2 Diabetes
The company has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide
Dr. Reddy’s Laboratories gets EIR for Andhra Pradesh’s manufacturing facility
USFDA has classified the inspection outcome as Voluntary Action Indicated
Dr. Reddy’s acquires specialty brands Progynova, Cyclo-Progynova in India
The acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment
Dr. Reddy’s Laboratories reports 14% fall in Q3 consolidated net profit
Consolidated total income increased by 5.75% at Rs 9,022.20 crore for Q3FY26
Dr. Reddy’s Laboratories launches Olopatadine Hydrochloride Ophthalmic Solution
The company’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is available in a 2.5 mL bottle
Dr. Reddy’s gets 5 observations from USFDA for Srikakulam formulations facility
The USFDA conducted a GMP and a Pre-Approval Inspection (PAI) of the said facility
Dr. Reddy’s Laboratories’ arm partners with Immutep’s wholly-owned subsidiary
Dr. Reddy’s Laboratories SA has entered into a strategic collaboration and exclusive Licensing agreement with Immutep SAS
Dr. Reddy’s Laboratories gets European Commission approval for AVT03
In May 2024, Dr. Reddy’s Laboratories and Alvotech entered into a license and supply agreement for the commercialization of AVT03
Dr Reddy’s Laboratories reports 7% rise in Q2 consolidated net profit
The consolidated total income of the company increased by 9.66% at Rs 9152.20 crore for Q2FY26
Dr. Reddy’s gets EIR for formulations manufacturing facility in Andhra Pradesh
USFDA has classified the inspection outcome as Voluntary Action Indicated
Dr. Reddy’s Lab’s arm recalls affected lot of Succinylcholine Chloride injection in US
The company initiated the nationwide (US) Class II recall on September 26 this year
Dr. Reddy’s Laboratories launches novel molecule ‘Tegoprazan’ in India
Tegoprazan is a next-generation potassium-competitive acid blocker
USFDA completes PAI at Dr. Reddy’s biologics manufacturing facility in Hyderabad
The inspection was conducted from September 4, 2025 to September 12, 2025`
Dr. Reddy’s Laboratories to acquire STUGERON brand
The said acquisition will strengthen Dr. Reddy’s Central Nervous System Portfolio in India and Emerging Markets through its foray into the antivertigo segment
Dr. Reddy’s Laboratories gets EIR for API manufacturing facility in Telangana
The USFDA has classified the inspection outcome as Voluntary Action Indicated
Dr. Reddy’s makes investment of Rs 565.40 crore in DRL Russia
The fund infused by the company into DRL Russia will be used for working capital requirements
Dr Reddy’s Laboratories reports marginal rise in Q1 consolidated net profit
Total consolidated income of the company increased by 12.41% at Rs 8862.40 crore for Q1FY26
Dr. Reddy’s gets EIR for API manufacturing facility in New York
The USFDA has classified the inspection outcome as Voluntary Action Indicated
USFDA completes GMP and Pre-Approval Inspection at Dr. Reddy’s Andhra Pradesh facility
The inspection was conducted from July 10, 2025 to July 18, 2025
Dr. Reddy’s Laboratories, Alvotech enter into license agreement
Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities
USFDA completes GMP inspection at Dr. Reddy’s Telangana API facility
The inspection was conducted from May 19, 2025 to May 24, 2025
USFDA completes GMP inspection at Dr. Reddy’s API Middleburgh facility in New York
The inspection was conducted from May 12, 2025 to May 16, 2025
Dr. Reddy’s Laboratories reports 21% rise in Q4 consolidated net profit
The total consolidated income of the company increased by 23.79% at Rs 9,050.50 crore for Q4FY25
Dr. Reddy’s Laboratories expands partnership with Sanofi Healthcare
The medication is also administered in children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season
Dr. Reddy’s arm recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection in US
The company has issued the Class 1 nationwide (US) recall on March 13, 2025
Dr. Reddy’s arm inks commercialization and license agreements for biosimilars
Dr. Reddy’s will be responsible for seeking regulatory approvals as well as commercialization in the licensed territories
Dr. Reddy’s arm sells membership interests in Dr. Reddy’s Laboratories Louisiana
Dr. Reddy’s Laboratories Louisiana has ceased to be a wholly owned subsidiary of Dr. Reddy’s Laboratories Inc. and a step-down wholly owned subsidiary of Dr. Reddy’s Laboratories
Dr. Reddy’s gets EIR for API manufacturing facility in Hyderabad
The USFDA has classified the inspection as VAI and concluded that the inspection is ‘closed’ under 21 CFR 20.64(d)(3)
Dr. Reddy’s Laboratories reports marginal rise in Q3 consolidated net profit
Total income of the company increased by 14.47% at Rs 8531.40 crore for Q3FY25
Dr. Reddy’s arm to sell membership interests in DRLL
Consequently, Dr. Reddy’s Laboratories Louisiana LLC will cease to be a wholly owned subsidiary of Dr. Reddy’s Laboratories Inc
Dr. Reddy’s Laboratories’ arm incorporates wholly-owned subsidiary in Finland
Dr. Reddy’s Finland Oy is a step-down wholly-owned subsidiary of the company
Dr. Reddy’s Laboratories launches Toripalimab in India
It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, EMA, MHRA, and others for the treatment of adults with RM-NPC
Dr. Reddy’s Laboratories’ arm recalling Morphine Sulfate extended-release tablets
Dr Reddy’s Laboratories Inc is also recalling another 532 100-count bottles of the medication in 30 mg strength for the same reason
Dr. Reddy’s to invest up to Rs 600 crore in step-down wholly owned subsidiary
The fund will be used for working capital requirements
Dr. Reddy’s Laboratories reports 9% fall in Q2 consolidated net profit
Total consolidated income of the company increased by 15.63% at Rs 8345.70 crore for Q2FY25
Dr. Reddy’s Laboratories launches drug to treat chronic constipation
Dr Reddy’s is the first company to receive approval for and launch such a drug (Elobixibat) in India
Dr. Reddy’s Laboratories’ arm incorporates new wholly-owned subsidiary
Accordingly, Dr. Reddy’s Denmark ApS is a step-down wholly-owned subsidiary of the company
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences
The agreement is for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries
Dr. Reddy’s makes investment of $620 million in DRL SA
DRL SA has allotted 6,200,000 non-convertible preference shares each with a nominal value of $100 to the company on September 27, 2024
USFDA completes GMP inspection at Dr. Reddy’s Laboratories’ R&D centre
The inspection closed with zero observations
Dr. Reddy’s Laboratories’ arm to sell entire stake in Dr. Reddy’s Venezuela C.A., Venezuela
Consequently, Dr. Reddy’s Venezuela C.A. will cease to be a wholly owned subsidiary of Dr. Reddy’s Swiss as well as step down wholly owned subsidiary of the Company
Dr. Reddy’s launches drug-free migraine management wearable device Nerivio in Germany
The launch marks the company’s entry into digital therapeutics in Europe
Dr. Reddy’s, Bayer sign marketing, distribution agreement for second brand of Vericiguat in India
Vericiguat works on a pathway not currently targeted by existing heart failure treatments and can reduce the combined risk of cardiovascular death and heart failure hospitalization in such patient
Dr. Reddy’s Laboratories enters into exclusive partnership with Sanofi Healthcare India
The company has entered into an exclusive partnership to promote and distribute their vaccine brands across private markets in India
Dr. Reddy’s Laboratories enters into license agreement with Pharmazz
As per the agreement, Dr. Reddy’s has received exclusive rights to market and distribute Centhaquine in India
Dr. Reddy’s Laboratories launches Versavo in United Kingdom
Versavo is the first Dr. Reddy’s biosimilar product to be approved and launched in the UK
Dr. Reddy’s Laboratories incorporates wholly owned subsidiary
The certificate of incorporation has been issued by the Ministry of Corporate Affairs, Government of India, on March 14, 2024
Dr. Reddy’s gets EIR from USFDA for formulations manufacturing facility in Hyderabad
The USFDA has classified the inspection as Voluntary Action Indicated and concluded that the inspection is ‘closed’ under 21 CFR 20.64(d)(3)
Dr.Reddy’s Laboratories reports 11% rise in Q3 consolidated net profit
Total consolidated income of the company increased by 8.83% at Rs 7453.00 crore for Q3FY24
Dr Reddy’s recalling over 8,000 bottles of generic drug in US due to a packaging error
The affected lot was produced at Dr Reddy’s Bachupally-based plant near Hyderabad
Dr. Reddy’s acquires MenoLabs business
The company acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause
Dr. Reddy’s Laboratories’ arm acquires 6.46% stake in Edity Therapeutics
The funds invested by the company would be utilized by Edity to further develop its technology platform
USFDA completes GMP, Pre-Approval Inspection at Dr. Reddy’s R&D centre in Hyderabad
The inspection was conducted from December 4, 2023 to December 8, 2023
Dr. Reddy’s Laboratories’ arm enters into agreement with Coya Therapeutics
Under the terms of the Agreement, Coya has granted Dr. Reddy’s an exclusive license to commercialize COYA 302
Dr. Reddy’s Laboratories recalling 1,656 bottles of Montelukast sodium tablets in US market
The product is indicated to prevent wheezing, breathing difficulty, chest tightness, and coughing caused by asthma in adults
Dr. Reddy’s Laboratories rolls out Nerivio in India
Nerivio can be worn on the upper arm
Dr. Reddy’s acquires 26% stake in O2 Renewable Energy IX
The object of acquisition is to access renewable power through solar and wind power plants through ISTS under captive structure
USFDA completes routine cGMP inspection at formulations manufacturing facility of Dr. Reddy’s
USFDA has issued a Form 483 with ten observations
Dr. Reddy’s Laboratories reports 33% rise in Q2 consolidated net profit
Total consolidated income of the company increased by 13.26% at Rs 7217.60 crore for Q2FY24
USFDA completes pre-approval inspection at biologics manufacturing facility of Dr. Reddy’s
The company has been issued a Form 483 with nine observations
Dr. Reddy’s Laboratories’ arm incorporates wholly-owned subsidiary in Jamaica
Dr. Reddy’s Laboratories Jamaica is a step-down wholly-owned subsidiary of the company
Dr. Reddy’s Laboratories gets nod to incorporate Wholly-owned Subsidiary
The Board of Directors of the Company at its meeting held on September 28, 2023, has approved the same
Dr. Reddy’s Laboratories launches Saxagliptin and Metformin Hydrochloride Extended-Release Tablets
Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30
Dr. Reddy’s Laboratories reports 18% rise in Q1 consolidated net profit
Total consolidated income of the company increased by 13.88% at Rs 6931.90 crore for Q1FY24
USFDA completes PAI, GMP inspection at Dr. Reddy’s Laboratories’ Andhra Pradesh facility
The inspection closed with zero observations and a classification of No Action Indicated
Dr. Reddy’s Laboratories to invest in O2 Renewable Energy IX
The company has entered into a Security Subscription and Shareholders’ agreement with TEQ Green Power XI and O2 Power SG Pte
Dr. Reddy’s proposed rituximab biosimilar application accepted for review by USFDA
This closely follows acceptance of its rituximab biosimilar dossier for review by two other regulatory agencies-EMA and the United Kingdom’s MHRA
Dr Reddy’s Laboratories eyeing to enhance presence in emerging segments like nutraceuticals
The company aims to get into integrated digital healthcare services as part of its future growth plans
Dr. Reddy’s selects AWS as preferred cloud provider
As part of the collaboration, the company has migrated its SAP platform entirely onto AWS
Dr Reddy’s forays into child nutrition space with launch of gummies
CeleHealth Kidz Immuno Plus Gummies aim to address the nutritional requirements due to the growing issues around child immunity in India
Dr. Reddy’s Laboratories enters into trade generics business in India
The new business will further the company’s goal of reaching over 1.5 billion patients by 2030
USFDA completes GMP inspection at Dr. Reddy’s API manufacturing facility in Bollaram
The inspection closed with zero observations
USFDA completes inspection at Dr. Reddy’s formulations manufacturing facility in Srikakulam
The inspection was conducted from May 8, 2023 to May 12, 2023
Dr. Reddy’s Laboratories gets one observations from USFDA for Hyderabad facility
The inspection was conducted from May 1, 2023 to May 5, 2023
Dr. Reddy’s Laboratories launches Regadenoson Injection in U.S. market
The company’s Regadenoson Injection is supplied as single-dose pre-filled syringes
Dr. Reddy’s Laboratories launches Treprostinil Injection in U.S. market
The company’s Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials
Dr Reddy’s signs deal to divest certain non-core brands in dermatology to Eris Lifesciences
As per IQVIA MAT December 2022, the divested portfolio saw sales of Rs 60 crore in India
Dr Reddy’s Laboratories’ arm recalling 4,320 bottles of Tacrolimus Capsules in US
The affected lot was produced at the company’s Bachupally-based manufacturing plant
Dr. Reddy’s Laboratories’ arm inks pact to acquire Mayne Pharma’s U.S. generic prescription product portfolio
The acquisition will complement Dr. Reddy’s U.S. retail prescription pharmaceutical business with limited competition products
Dr. Reddy’s Laboratories included in Bloomberg GEI 2023 for sixth consecutive year
The 2023 index includes 484 companies representing 11 sectors, 45 countries and a market capitalization of $16 trillion
Dr. Reddy’s launches Difluprednate Ophthalmic Emulsion in US market
Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24
Dr. Reddy’s Laboratories reports 75% rise in Q3 consolidated net profit
Total consolidated income of the company increased 26.96% at Rs 6848.50 crore for Q3FY23
Dr. Reddy’s completes full set of clinical studies of rituximab biosimilar for filing in U.S., Europe
The company’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets
Dr Reddy’s reduces price of cardiovascular drug ‘Cidmus’
This price reduction will further widen access to this trusted and established brand
Dr. Reddy’s acquires trademark rights of breast cancer drug PRIMCYV from Pfizer Products
Since May 2022, the company has been marketing the drug in collaboration with Pfizer Products India under the brand name PRIMCYV in India
Dr. Reddy’s inks pact with Theranica
Nerivio is a wearable migraine treatment that stimulates the body’s pain receptors in order to relieve acute and chronic migraine pain
Dr. Reddy’s Laboratories completes Phase 1 study of proposed biosimilar of Tocilizumab
The company’s Tocilizumab biosimilar candidate ’DRL_TC’ successfully met its primary and secondary endpoints in a Phase 1 study
Dr. Reddy’s Laboratories’ arm enters into agreement to sell certain assets, liabilities
The agreed consideration for the assets and liabilities of the said site is Euro 1
Dr. Reddy’s Laboratories’ arm reports results of AUR101 in Phase II Study in Patients with moderate to severe psoriasis
Aurigene will be closing the clinical development of AUR101 in psoriasis`
Dr. Reddy’s arm recalls over 48,000 cartons of drug used to treat sneezing, runny or stuffy nose
According to USFDA, the company is recalling the affected lot due to ‘failed stability specifications’
Dr Reddy’s Laboratories earmarks capex of around Rs 1,500 crore for FY23
The company also plans to utilise the capital for adding capacities to existing plants, firm up R&D activities and further invest in digitisation projects
Dr. Reddy’s Laboratories reports 12% rise in Q2 consolidated net profit
Total consolidated income of the company increased by 6.34% at Rs 6372.60 crore for Q2FY23
Dr Reddy’s recalling Phytonadione Injectable Emulsion in US
According to the USFDA, the company is recalling the affected lot due to failed stability specifications
WEF recognizes Dr. Reddy’s Hyderabad factory as part of Global Lighthouse Network
With this recognition, the facility joins the GLN
Dr. Reddy’s lab launches Lenalidomide Capsules in US
With this volume-limited launch, Dr. Reddy’s is eligible for first-to market, 180 days of generic drug exclusivity for Lenalidomide Capsules
Dr Reddy’s Laboratories gets EIR for manufacturing facility in Andhra Pradesh
The agency has concluded that the inspection is ‘closed’
Dr Reddy’s, Intercept Pharmaceuticals enter into settlement agreement
Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis
Dr. Reddy’s arm recalls 5,531 cartons of Lansoprazole tablets
The New Jersey-based firm initiated the Class II nationwide recall on July 13
Dr Reddy’s launches store-brand equivalent of Allegra-D 24 HR in US market
Allegra-D 24 HR had U.S. retail sales of approximately $45 million as of May 2022 according to IRI
Dr. Reddy’s Laboratories launches Fesoterodine Fumarate Extended-Release Tablets
Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30
Dr Reddy’s Laboratories’ Andhra Pradesh plant gets two observations from USFDA
The inspection was conducted from June 30, 2022 to July 07, 2022
Dr. Reddy’s Laboratories targeting to triple reach to 1.5 billion patients by 2030
Besides, by 2030 the company will use 100 per cent renewable power and it will also be carbon-neutral in direct emissions
Dr. Reddy’s Laboratories’ arm collaborates with EQRx
The partnership aims to accelerate the development of drugs candidates in the area of oncology
Dr. Reddy’s Laboratories launches Sorafenib Tablets in US market
Dr. Reddy’s Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120
Dr. Reddy’s Laboratories’ arm inks exclusive global license agreement with Olema
Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights to a pre-existing Aurigene program
Dr. Reddy’s Laboratories launches Pemetrexed for injection in US market
The company’s Pemetrexed for Injection, is supplied in 100 mg and 500 mg single-dose vials
Dr. Reddy’s Laboratories, Senores Pharmaceuticals launch Ketorolac Tromethamine Tablets
Dr. Reddy’s Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100